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Lifestyle modification and oral antidiabetic drugs are first line treatment measures in patients with type 2 diabetes mellitus (T2DM). Over time, progressive beta cell dysfunction results in deteriorating glycemic control requiring insulin therapy. However, insulin is often associated with weight gain and increased risk of hypoglycemia \[[@CR1]\]. Together with the need for (multiple) injections, insulin therapy frequently meets reluctance in both patients and physicians, and initiation of therapy is often delayed \[[@CR2]\]. Several trials showed that Glucagon-like peptide-1 (GLP-1) receptor agonists as monotherapy or in combination with one or more oral antidiabetic agent have beneficial metabolic effects leading to improved glycemic control with a low risk of hypoglycemia, and weight loss \[[@CR3]\]. They are now recommended as one of several two-drug combination therapies, if metformin monotherapy does not achieve/maintain the defined glycated hemoglobin (HbA1c) target over 3 months \[[@CR4]\].

Several reports demonstrated favorable effects of a combination therapy of a GLP-1 receptor agonist with insulin \[[@CR5]\]. However, only few studies included the use of liraglutide \[[@CR6]--[@CR10]\], and follow-up time was short. Despite these limited data, liraglutide is widely used (off-label) as add-on therapy in patients on various insulin regimens and oral antidiabetic drugs. In 2013, liraglutide was officially approved for use in combination with basal insulin in Europe (and the US). The aim of this observational study was to retrospectively assess the efficacy and safety of liraglutide as add-on therapy to insulin in a daily clinical practice setting for a duration up to 24--28 months.

Methods {#Sec2}
=======

Eligible participants were adults (18--80 years) with T2DM, BMI ≥ 28 kg/m^2^ and HbA1c values of 6.5--10% treated with metformin ± another oral antidiabetic drug and insulin. Exclusion criteria were pregnancy and intolerance for liraglutide. The authors reviewed the charts of all patients with T2DM with liraglutide being added-on to insulin from October 2009 until December 2011 at their outpatient clinic in a tertiary referral hospital. Weight, body mass index (BMI), HbA1c and insulin dose (units/day, units/kg/day) were assessed 5--8 months prior to liraglutide, at baseline, after 3, 6, 12--16 and 24--28 months.

Starting dose of liraglutide was 0.6 mg once daily, with an increase to 1.2 mg after 2 weeks. During the treatment period, no additional antidiabetic drug was initiated. Oral drugs and insulin dosage were individually reduced by the attending physician according to current glucose control. As the outpatient clinic is part of a teaching hospital, all physicians followed the same treatment strategies according to the guidelines of the Swiss Society of Endocrinology and Diabetes \[[@CR11]\]. Hypoglycemic events were assessed by patient interview and patients' blood glucose meter readings were imported into the DIABASS^®^ Pro Software, Mediaspects GmbH, Konstanz, Germany. Severe hypoglycemia was defined as an event requiring assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions \[[@CR12]\].

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients for being included in the study.

For statistical analysis linear mixed models with random intercept were used to examine changes in endpoints over time from baseline, after 3, 6, 12--16 and 24--28 months. Such regression models do not require complete data (unlike in analysis of variance), so all available data was analyzed \[[@CR13]\]. All analysis was performed in the R programming language (version 3.0.1, R Core Team 2013 Center for Statistics, Copenhagen, Denmark). The package lme4 was used to estimate the mixed models, while the multcomp \[[@CR14]\] was used to compute the *p* values and confidence intervals.
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A total of 36 patients was on this combined therapy regimen. After the baseline visit, four patients preferred to be followed up by their family physician and were therefore not included in this follow-up. Three patients stopped liraglutide due to exanthema at the injection site, nausea and abdominal pain, respectively. Among the remaining 29 patients, median age was 59 years \[interquartile range (IQR) 53--67\], disease duration 11 years (IQR 5--13), HbA1c 7.7% (IQR 7.0--8.6), weight 99.8 kg (IQR 81--110) and BMI 33.5 kg/m^2^ (IQR 29.4--37.6). At baseline, 17 were on basal insulin, 2 on prandial insulin and 10 on multiple insulin injections. In addition, 24 patients were on metformin, 12 on sulfonylureas, and 6 on other oral antidiabetic agents.

Median HbA1c decreased significantly from 7.7% (IQR 7.0--8.6) at baseline to 6.8% (IQR 6.5--7.7, *p* = 0.001) at 3 months and 6.9%, (IQR 6.3--7.6, *p* = 0.0001) at 6 months, but re-increased at 12--16 months (median 7.2%, IQR 6.7--7.9, *p* = 0.32) and 24--28 months (median 7.5%, IQR 7.1--8.2, *p* = 1.0). HbA1c prior to intervention was lower (median 7.3%, IQR 7.1--7.9) than at baseline. Weight and BMI decreased significantly from 99.8 kg and 33.5 kg/m^2^ (IQR 81--110 and 29.4--37.6) respectively at baseline to 97.7 kg and 31.9 kg/m^2^ (IQR 81.2--108.2 and 29.4--36), (*p* = 0.023 and 0.027) at 3 months. However weight and BMI increased again after 6 months (median 97.5 kg and 31.5 kg/m^2^, IQR 84.5.5--111.5, *p* = 0.16 and 29.4--35.1, *p* = 0.15), at 12--16 months (100.5 kg and 34.1 kg/m^2^, IQR 100.5--109.5, *p* = 0.17 and 30.7--36.7, *p* = 0.16) and at 24--28 months (106.4 kg and 36.4 kg/m^2^, IQR 96.9--118, *p* = 1.0 and 30.9--38.4, *p* = 1.0). Insulin dosage did not change significantly over time (Fig. [1](#Fig1){ref-type="fig"}). However, during follow-up, three patients (10.3%) were able to completely stop insulin therapy, and two patients (6.9%) could simplify their multiple daily insulin injection regimens to basal insulin at bedtime only. Furthermore, sulfonylureas were stopped in 5 of 12 patients (41.7%) and all other antidiabetic drugs beside metformin were stopped (e.g. glitazones, glinides). No severe hypoglycemia occurred over the entire period. Overall, 5 patients (15.6%) out of 32 followed-up patients discontinued liraglutide due to side effects. Three patients stopped liraglutide due to exanthema at the injection site, nausea or abdominal pain at the beginning and two patients discontinued liraglutide due to nausea/vomiting and pain at the injection site after 3.5 and 12 months.Fig. 1Course of glycated hemoglobin (HbA1c), insulin (total units and units per kg body weight), weight and body mass index (BMI) prior (T-1), at baseline (T0) and during follow-up after 3 (T1), 6 (T2), 12--16 (T3) and 24--28 months (T4)
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This retrospective study shows that liraglutide as add-on therapy to insulin therapy decreases HbA1c and weight during the first 6 months with a fading effect thereafter. No serious hypoglycemic event occurred. The most frequently reported side effects were nausea/vomiting and pain/exanthema at the injection site, leading to discontinuation of liraglutide in 15.6% of the patients.

The short-term findings on HbA1c and weight reduction are in accordance with earlier randomized and observational studies over 12 weeks on liraglutide added to insulin, which found a reduction of HbA1c by 1.4--1.9% and body weight by 5.1--5.6 kg, respectively \[[@CR7], [@CR8]\].

A recent report showed a decrease in HbA1c levels of 0.77% and 4.5 kg weight reduction over 26 weeks \[[@CR10]\]. A most recent meta-analysis of 15 studies on GLP-1 agonists in combination with basal insulin with a maximum observation time of 36 weeks (mean 24.8 weeks) yielded an HbA1c reduction of 0.44% and weight loss of 3.22 kg \[[@CR15]\]. The longest follow-up was in a retrospective study until 38 weeks, where body weight also re-increased in 20 patients on liraglutide or exenatide in combination with insulin \[[@CR6]\], similar to the patient population in the current study. Results with longer follow-up time are only available in the reverse situation of basal insulin added on to metformin and liraglutide in a prospective study, showing sustained HbA1c and weight reduction even after 52 weeks \[[@CR16]\].

Several reasons may account for the unsustained effect of liraglutide on body weight and HbA1c beyond 6 months in the patients presented here. Firstly, reduction of insulin dose or termination of oral antidiabetic drugs may have led to the re-increase in HbA1c. Secondly, no antidiabetic treatment has been shown to prevent deterioration of β-cell function, which drives the natural history of the disease \[[@CR1]\]. Thirdly, the authors often observe that patient adherence, especially regarding dietary restrictions, fades after a few months of starting liraglutide, which may be explained by the disappearing gastrointestinal side effects. Subjects willing to participate in a prospective study are supposedly more motivated and adherent to improve their glycemic control in general. Finally, subjects early achieving adequate glycemic control within a few weeks or months usually return to their referring physicians, whereas the more challenging patients remained in the tertiary clinic and were eligible for this study. The clinical setting reflects a real world situation and shows the difficulties which diabetologists face in their daily work.

In contrast to other studies with GLP-1 receptor agonists and insulin \[[@CR17]\], there was no statistically significant reduction in daily insulin dose in the present study. However, a remarkable proportion of the patients either completely ceased insulin or at least were able to omit prandial insulin injections. Moreover, in many of the patients, oral antidiabetic drugs (beside metformin) could be stopped, which is especially beneficial for patients with sulfonylureas bearing an increased risk of hypoglycemia.

In accordance with earlier reports, liraglutide was well tolerated. Remarkably, no events of severe hypoglycemia were observed in the present cohort. The dropout rate of 15.6% due to side effects was comparable to other reports \[[@CR18], [@CR19]\].

Limitations of this study are the small patient number and potentially heterogeneous patient characteristics, including patients with long-standing diabetes as well as the retrospective study design. As this was an observational study, there was no control group. The fact that HbA1c was increasing before baseline may point to a regression towards the mean. The setting reflects the real life situation in an outpatient clinic of a tertiary referral hospital covering around 500,000 inhabitants. During the observational period, combination therapy of liraglutide and insulin was not yet approved by Swissmedic (Swiss agency for the authorisation and supervision of therapeutic products), which explains the small number of patients. However, a major strength of this study is the long observational period of up to 24--28 months, as compared to most earlier studies with a follow-up time of usually 24 weeks with a few lasting up to 38 weeks. In the meantime, add-on therapy of liraglutide to basal insulin was approved due to its unequivocal positive effect. The combination of liraglutide with multiple insulin injections, however, is still awaiting approval.

Conclusion {#Sec5}
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Adding liraglutide to pre-existing insulin therapy in T2DM reduces HbA1c and body weight significantly during the initial 6 months of treatment, but there may be a non-sustainable effect during long-term treatment.
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